Impact of antibiotic de-escalation on clinical outcomes in community-acquired pneumococcal pneumonia

D Viasus, AF Simonetti, C Garcia-Vidal… - Journal of …, 2017 - academic.oup.com
Background Although antibiotic de-escalation is regarded as a measure that reduces
selection pressure, adverse drug effects and costs, evidence supporting this practice in …

Impact of antibiotic de-escalation on clinical outcomes in community-acquired pneumococcal pneumonia.

D Viasus, AF Simonetti, C Garcia-Vidal, J Niubó… - 2017 - cabidigitallibrary.org
Background: Although antibiotic de-escalation is regarded as a measure that reduces
selection pressure, adverse drug effects and costs, evidence supporting this practice in …

Impact of antibiotic de-escalation on clinical outcomes in community-acquired pneumococcal pneumonia.

D Viasus, AF Simonetti, C Garcia-Vidal… - The Journal of …, 2016 - europepmc.org
Background Although antibiotic de-escalation is regarded as a measure that reduces
selection pressure, adverse drug effects and costs, evidence supporting this practice in …

[引用][C] Impact of antibiotic de-escalation on clinical outcomes in community-acquired pneumococcal pneumonia

D Viasus, AF Simonetti, C Garcia-Vidal… - Journal of Antimicrobial …, 2016 - cir.nii.ac.jp
Impact of antibiotic de-escalation on clinical outcomes in community-acquired pneumococcal
pneumonia | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 …

Impact of antibiotic de-escalation on clinical outcomes in community-acquired pneumococcal pneumonia

D Viasus, AF Simonetti… - The Journal of …, 2017 - pubmed.ncbi.nlm.nih.gov
Background Although antibiotic de-escalation is regarded as a measure that reduces
selection pressure, adverse drug effects and costs, evidence supporting this practice in …